{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:15:00Z","timestamp":1790784900458,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375633"],"award-info":[{"award-number":["PNRR-MAD-2022-12375633"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10674-6","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:02:23Z","timestamp":1720778543000},"page":"861-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-6329","authenticated-orcid":false,"given":"Anna","family":"Alisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"5","key":"10674_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N M\u00e9ndez-S\u00e1nchez","year":"2022","unstructured":"M\u00e9ndez-S\u00e1nchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388\u2013390","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10674_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"7","key":"10674_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014","journal-title":"Gastroenterology"},{"issue":"3","key":"10674_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology (Baltimore, MD). 2021;73(3):1194\u20131198","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"10674_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","volume":"32","author":"S Lim","year":"2021","unstructured":"Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500\u2013514","journal-title":"Trends Endocrinol Metab"},{"key":"10674_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000735","author":"S Driessen","year":"2023","unstructured":"Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction associated steatotic liver disease and the heart. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000735","journal-title":"Hepatology"},{"issue":"6","key":"10674_CR7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u20131986","journal-title":"Hepatology"},{"key":"10674_CR8","doi-asserted-by":"publisher","first-page":"1110536","DOI":"10.3389\/fnut.2023.1110536","volume":"10","author":"M Maestri","year":"2023","unstructured":"Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies. Front Nutr. 2023;10:1110536","journal-title":"Front Nutr"},{"key":"10674_CR9","doi-asserted-by":"publisher","first-page":"101859","DOI":"10.1016\/j.smim.2023.101859","volume":"71","author":"SG Rodrigues","year":"2024","unstructured":"Rodrigues SG, van der Merwe S, Krag A, Wiest R. Gut-liver axis: pathophysiological concepts and medical perspective in chronic liver diseases. Semin Immunol. 2024;71:101859","journal-title":"Semin Immunol"},{"key":"10674_CR10","doi-asserted-by":"publisher","first-page":"121614","DOI":"10.1016\/j.lfs.2023.121614","volume":"321","author":"L Luo","year":"2023","unstructured":"Luo L, Chang Y, Sheng L. Gut-liver axis in the progression of nonalcoholic fatty liver disease: from the microbial derivatives-centered perspective. Life Sci. 2023;321:121614","journal-title":"Life Sci"},{"issue":"7","key":"10674_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","volume":"20","author":"O Pabst","year":"2023","unstructured":"Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20(7):447\u2013461","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10674_CR12","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533","journal-title":"PLoS Biol"},{"issue":"5","key":"10674_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020\u20131032","journal-title":"Gut"},{"issue":"1","key":"10674_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121\u2013141","journal-title":"Cell"},{"issue":"1","key":"10674_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/microorganisms7010014","volume":"7","author":"E Rinninella","year":"2019","unstructured":"Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14","journal-title":"Microorganisms"},{"key":"10674_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","volume":"65","author":"JR Marchesi","year":"2016","unstructured":"Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330\u2013339","journal-title":"Gut"},{"issue":"5","key":"10674_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/apt.14910","volume":"48","author":"F Tovoli","year":"2018","unstructured":"Tovoli F, Negrini G, Far\u00ec R, Guidetti E, Faggiano C, Napoli L, et al. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. Aliment Pharmacol Ther. 2018;48(5):538\u2013546","journal-title":"Aliment Pharmacol Ther"},{"issue":"14","key":"10674_CR18","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.3390\/nu14142942","volume":"14","author":"A Raiteri","year":"2022","unstructured":"Raiteri A, Granito A, Faggiano C, Giamperoli A, Catenaro T, Negrini G, et al. Hepatic steatosis in patients with celiac disease: the role of packaged gluten-free foods. Nutrients. 2022;14(14):2942","journal-title":"Nutrients"},{"issue":"12","key":"10674_CR19","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","volume":"62","author":"T Le Roy","year":"2013","unstructured":"Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787\u20131794","journal-title":"Gut"},{"issue":"5","key":"10674_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279\u2013297","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10674_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2023.01.004","volume":"52","author":"TM Barber","year":"2023","unstructured":"Barber TM, Hanson P, Weickert MO. Metabolic-associated fatty liver disease and the gut microbiota. Endocrinol Metab Clin North Am. 2023;52(3):485\u2013496","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10674_CR22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/medicina59030594","volume":"59","author":"L Abenavoli","year":"2023","unstructured":"Abenavoli L, Scarlata GGM, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B, et al. Metabolic-dysfunction-associated fatty liver disease and gut microbiota: from fatty liver to dysmetabolic syndrome. Medicina (Kaunas). 2023;59(3):594","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10674_CR23","doi-asserted-by":"publisher","first-page":"e13646","DOI":"10.1111\/obr.13646","volume":"25","author":"X Su","year":"2024","unstructured":"Su X, Chen S, Liu J, Feng Y, Han E, Hao X, et al. Composition of gut microbiota and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Rev. 2024;25(1):e13646","journal-title":"Obes Rev"},{"issue":"5","key":"10674_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmgh.2021.02.007","volume":"11","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol. 2021;11(5):1463\u20131482","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"10674_CR25","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/ijms23020662","volume":"23","author":"R Forlano","year":"2022","unstructured":"Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou P. The intestinal barrier and its dysfunction in patients with metabolic diseases and non-alcoholic fatty liver disease. Int J Mol Sci. 2022;23(2):662","journal-title":"Int J Mol Sci"},{"issue":"129","key":"10674_CR26","first-page":"136","volume":"61","author":"D Xin","year":"2014","unstructured":"Xin D, Zong-Shun L, Bang-Mao W, Lu Z. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology. 2014;61(129):136\u2013140","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"10674_CR27","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877\u20131887","journal-title":"Hepatology"},{"issue":"4","key":"10674_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jceh.2022.01.006","volume":"12","author":"K Kaushal","year":"2022","unstructured":"Kaushal K, Agarwal S, Sharma S, Goswami P, Singh N, Sachdev V, et al. Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: a proof-of-concept study. J Clin Exp Hepatol. 2022;12(4):1102\u20131113","journal-title":"J Clin Exp Hepatol"},{"issue":"12","key":"10674_CR29","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.3390\/ijms22126485","volume":"22","author":"F Fianchi","year":"2021","unstructured":"Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic fatty liver disease (NAFLD) as model of gut-liver axis interaction: from pathophysiology to potential target of treatment for personalized therapy. Int J Mol Sci. 2021;22(12):6485","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10674_CR30","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41598-018-19753-9","volume":"8","author":"HE Da Silva","year":"2018","unstructured":"Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8(1):1466","journal-title":"Sci Rep"},{"key":"10674_CR31","doi-asserted-by":"publisher","first-page":"770986","DOI":"10.3389\/fendo.2021.770986","volume":"12","author":"T Kessoku","year":"2021","unstructured":"Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, et al. Endotoxins and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12:770986","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10674_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MPG.0b013e3181c7bdf1","volume":"50","author":"A Alisi","year":"2010","unstructured":"Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50(6):645\u2013649","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10674_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hep.31056","volume":"72","author":"G Carpino","year":"2020","unstructured":"Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology. 2020;72(2):470\u2013485","journal-title":"Hepatology"},{"issue":"1","key":"10674_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/iid3.391","volume":"9","author":"Y Luo","year":"2021","unstructured":"Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis. 2021;9(1):59\u201373","journal-title":"Immun Inflamm Dis"},{"issue":"12","key":"10674_CR35","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596\u20131607","journal-title":"Nat Metab"},{"key":"10674_CR36","doi-asserted-by":"publisher","first-page":"1231520","DOI":"10.3389\/fendo.2023.1231520","volume":"14","author":"K Luo","year":"2023","unstructured":"Luo K, Chen Y, Fang S, Wang S, Wu Z, Li H. Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1231520","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10674_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12944-023-01947-4","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, Han M, Li M, Huang X, Feng R, Li W, et al. Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study. Lipids Health Dis. 2023;22(1):185","journal-title":"Lipids Health Dis"},{"issue":"7464","key":"10674_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541\u2013546","journal-title":"Nature"},{"issue":"4","key":"10674_CR39","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s00125-018-4550-1","volume":"61","author":"KH Allin","year":"2018","unstructured":"Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018;61(4):810\u2013820","journal-title":"Diabetologia"},{"issue":"7418","key":"10674_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55\u201360","journal-title":"Nature"},{"issue":"2","key":"10674_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/path.5134","volume":"246","author":"L Genser","year":"2018","unstructured":"Genser L, Aguanno D, Soula HA, Dong L, Trystram L, Assmann K, et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. J Pathol. 2018;246(2):217\u2013230","journal-title":"J Pathol"},{"issue":"1","key":"10674_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2015.05.020","volume":"22","author":"M Monteiro-Sepulveda","year":"2015","unstructured":"Monteiro-Sepulveda M, Touch S, Mendes-S\u00e1 C, Andr\u00e9 S, Poitou C, Allatif O, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab. 2015;22(1):113\u2013124","journal-title":"Cell Metab"},{"issue":"10215","key":"10674_CR43","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u20132196. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"},{"issue":"44","key":"10674_CR44","doi-asserted-by":"publisher","first-page":"e2308511120","DOI":"10.1073\/pnas.2308511120","volume":"120","author":"R Sender","year":"2023","unstructured":"Sender R, Weiss Y, Navon Y, Milo I, Azulay N, Keren L, et al. The total mass, number, and distribution of immune cells in the human body. Proc Natl Acad Sci USA. 2023;120(44):e2308511120","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10674_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cells6040048","volume":"6","author":"M Freitas-Lopes","year":"2017","unstructured":"Freitas-Lopes M, Mafra K, David BA, Carvalho-Gontijo R, Menezes GB. Differential location and distribution of hepatic immune cells. Cells. 2017;6(4):48","journal-title":"Cells"},{"issue":"20","key":"10674_CR46","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1042\/CS20190654","volume":"135","author":"ML Cheng","year":"2021","unstructured":"Cheng ML, Nakib D, Perciani CT, MacParland SA. The immune niche of the liver. Clin Sci (Lond). 2021;135(20):2445\u20132466","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10674_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imm.13193","volume":"160","author":"Z Stamataki","year":"2020","unstructured":"Stamataki Z, Swadling L. The liver as an immunological barrier redefined by single-cell analysis. Immunology. 2020;160(2):157\u2013170","journal-title":"Immunology"},{"issue":"2","key":"10674_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","volume":"185","author":"M Guilliams","year":"2022","unstructured":"Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022;185(2):379\u2013396","journal-title":"Cell"},{"issue":"2","key":"10674_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2017.07.018","volume":"47","author":"F Sierro","year":"2017","unstructured":"Sierro F, Evrard M, Rizzetto S, Melino M, Mitchell AJ, Florido M, et al. A liver capsular network of monocyte-derived macrophages restricts hepatic dissemination of intraperitoneal bacteria by neutrophil recruitment. Immunity. 2017;47(2):374\u2013388","journal-title":"Immunity"},{"issue":"7","key":"10674_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429\u2013443","journal-title":"Nat Rev Immunol"},{"key":"10674_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","volume":"36","author":"P Kubes","year":"2018","unstructured":"Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. 2018;36:247\u2013277","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10674_CR52","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1038\/s41423-021-00690-z","volume":"18","author":"T Wang","year":"2021","unstructured":"Wang T, Ma C. The hepatic macrophage pool in NASH. Cell Mol Immunol. 2021;18(8):2059\u20132060","journal-title":"Cell Mol Immunol"},{"key":"10674_CR53","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","volume":"11","author":"H Li","year":"2020","unstructured":"Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol. 2020;11:1169","journal-title":"Front Immunol"},{"key":"10674_CR54","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3389\/fimmu.2019.02893","volume":"10","author":"JR Oates","year":"2019","unstructured":"Oates JR, McKell MC, Moreno-Fernandez ME, Damen MSMA, Deepe GS Jr, Qualls JE, et al. Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: the mac attack. Front Immunol. 2019;10:2893","journal-title":"Front Immunol"},{"issue":"6","key":"10674_CR55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jcmgh.2023.03.002","volume":"15","author":"J Vonderlin","year":"2023","unstructured":"Vonderlin J, Chavakis T, Sieweke M, Tacke F. The multifaceted roles of macrophages in NAFLD pathogenesis. Cell Mol Gastroenterol Hepatol. 2023;15(6):1311\u20131324","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"10674_CR56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.immuni.2022.01.008","volume":"55","author":"E Barreby","year":"2022","unstructured":"Barreby E, Aouadi M. To be or not to be a hepatic niche macrophage. Immunity. 2022;55(2):198\u2013200","journal-title":"Immunity"},{"issue":"1","key":"10674_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","volume":"1","author":"S Lefere","year":"2019","unstructured":"Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Rep. 2019;1(1):30\u201343","journal-title":"JHEP Rep"},{"issue":"11","key":"10674_CR58","doi-asserted-by":"publisher","first-page":"100877","DOI":"10.1016\/j.jhepr.2023.100877","volume":"5","author":"MM Chan","year":"2023","unstructured":"Chan MM, Daemen S, Beals JW, Terekhova M, Yang BQ, Fu CF, et al. Steatosis drives monocyte-derived macrophage accumulation in human metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023;5(11):100877","journal-title":"JHEP Rep"},{"issue":"2","key":"10674_CR59","doi-asserted-by":"publisher","first-page":"108626","DOI":"10.1016\/j.celrep.2020.108626","volume":"34","author":"S Daemen","year":"2021","unstructured":"Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 2021;34(2):108626","journal-title":"Cell Rep"},{"issue":"6","key":"10674_CR60","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s42255-019-0076-1","volume":"1","author":"JT Haas","year":"2019","unstructured":"Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, et al. Transcriptional network analysis implicates altered hepatic immune function in nash development and resolution. Nat Metab. 2019;1(6):604\u2013614","journal-title":"Nat Metab"},{"key":"10674_CR61","doi-asserted-by":"publisher","first-page":"641240","DOI":"10.3389\/fimmu.2021.641240","volume":"12","author":"N M\u00e9ndez-S\u00e1nchez","year":"2021","unstructured":"M\u00e9ndez-S\u00e1nchez N, C\u00f3rdova-Gallardo J, Barranco-Fragoso B, Eslam M. Hepatic dendritic cells in the development and progression of metabolic steatohepatitis. Front Immunol. 2021;12:641240","journal-title":"Front Immunol"},{"key":"10674_CR62","doi-asserted-by":"publisher","first-page":"e937528","DOI":"10.12659\/MSM.937528","volume":"28","author":"B Barranco-Fragoso","year":"2022","unstructured":"Barranco-Fragoso B, Pal SC, D\u00edaz-Orozco LE, Dorantes-Heredia R, Qi X, M\u00e9ndez-S\u00e1nchez N. Identification of hepatic dendritic cells in liver biopsies showing steatosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) associated with obesity. Med Sci Monit. 2022;28:e937528","journal-title":"Med Sci Monit"},{"issue":"6","key":"10674_CR63","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jhep.2017.01.008","volume":"66","author":"EC Heier","year":"2017","unstructured":"Heier EC, Meier A, Julich-Haertel H, Djudjaj S, Rau M, Tschernig T, et al. Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis. J Hepatol. 2017;66(6):1241\u20131250","journal-title":"J Hepatol"},{"issue":"6","key":"10674_CR64","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","volume":"27","author":"A Deczkowska","year":"2021","unstructured":"Deczkowska A, David E, Ramadori P, Pfister D, Safran M, Li B, et al. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med. 2021;27(6):1043\u20131054","journal-title":"Nat Med"},{"key":"10674_CR65","doi-asserted-by":"publisher","first-page":"1051076","DOI":"10.3389\/fendo.2022.1051076","volume":"13","author":"T Mao","year":"2022","unstructured":"Mao T, Yang R, Luo Y, He K. Crucial role of T cells in NAFLD-related disease: a review and prospect. Front Endocrinol (Lausanne). 2022;13:1051076","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10674_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","volume":"26","author":"MJ Wolf","year":"2014","unstructured":"Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26(4):549\u2013564","journal-title":"Cancer Cell"},{"key":"10674_CR67","doi-asserted-by":"publisher","first-page":"967410","DOI":"10.3389\/fimmu.2022.967410","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhang H, Yao Y, Zhang X, Guan Y, Zheng F. CD4+ T cell activation and inflammation in NASH-related fibrosis. Front Immunol. 2022;13:967410","journal-title":"Front Immunol"},{"issue":"1","key":"10674_CR68","doi-asserted-by":"publisher","first-page":"e153831","DOI":"10.1172\/jci.insight.153831","volume":"8","author":"A Woestemeier","year":"2023","unstructured":"Woestemeier A, Scognamiglio P, Zhao Y, Wagner J, Muscate F, Casar C, et al. Multicytokine-producing CD4+ T cells characterize the livers of patients with NASH. JCI Insight. 2023;8(1):e153831","journal-title":"JCI Insight"},{"issue":"74","key":"10674_CR69","doi-asserted-by":"publisher","first-page":"eabl3795","DOI":"10.1126\/sciimmunol.abl3795","volume":"7","author":"CC Clement","year":"2022","unstructured":"Clement CC, Osan J, Buque A, Nanaware PP, Chang YC, Perino G, et al. PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes. Sci Immunol. 2022;7(74):eabl3795","journal-title":"Sci Immunol"},{"issue":"2","key":"10674_CR70","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/hep.30952","volume":"71","author":"A Torres-Hernandez","year":"2020","unstructured":"Torres-Hernandez A, Wang W, Nikiforov Y, Tejada K, Torres L, Kalabin A, et al. \u03b3\u03b4 T cells promote steatohepatitis by orchestrating innate and adaptive immune programming. Hepatology. 2020;71(2):477\u2013494","journal-title":"Hepatology"},{"issue":"6","key":"10674_CR71","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/MEG.0b013e32831bc3d6","volume":"21","author":"K Tajiri","year":"2009","unstructured":"Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009;21(6):673\u2013680","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10674_CR72","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.23599","volume":"51","author":"WK Syn","year":"2010","unstructured":"Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1998\u20132007","journal-title":"Hepatology"},{"issue":"1","key":"10674_CR73","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1080\/07853890.2022.2108894","volume":"54","author":"S Zheng","year":"2022","unstructured":"Zheng S, Yang W, Yao D, Tang S, Hou J, Chang X. A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice. Ann Med. 2022;54(1):2233\u20132245","journal-title":"Ann Med"},{"issue":"4","key":"10674_CR74","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00281-022-00949-1","volume":"44","author":"H Mehta","year":"2022","unstructured":"Mehta H, Lett MJ, Klenerman P, Filipowicz SM. MAIT cells in liver inflammation and fibrosis. Semin Immunopathol. 2022;44(4):429\u2013444","journal-title":"Semin Immunopathol"},{"issue":"3","key":"10674_CR75","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7150\/ijbs.39016","volume":"16","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kong D, Wang H. Mucosal-associated invariant T cell in liver diseases. Int J Biol Sci. 2020;16(3):460\u2013470","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10674_CR76","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00281-021-00877-6","volume":"43","author":"AJ Highton","year":"2021","unstructured":"Highton AJ, Schuster IS, Degli-Esposti MA, Altfeld M. The role of natural killer cells in liver inflammation. Semin Immunopathol. 2021;43(4):519\u2013533","journal-title":"Semin Immunopathol"},{"key":"10674_CR77","doi-asserted-by":"publisher","first-page":"640869","DOI":"10.3389\/fimmu.2021.640869","volume":"12","author":"ML Mart\u00ednez-Chantar","year":"2021","unstructured":"Mart\u00ednez-Chantar ML, Delgado TC, Beraza N. Revisiting the role of natural killer cells in non-alcoholic fatty liver disease. Front Immunol. 2021;12:640869","journal-title":"Front Immunol"},{"issue":"1","key":"10674_CR78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D, et al. Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway. Cell Mol Gastroenterol Hepatol. 2022;13(1):257\u2013274","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"10674_CR79","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/hep.31889","volume":"74","author":"F Barrow","year":"2021","unstructured":"Barrow F, Khan S, Wang H, Revelo XS. The emerging role of B cells in the pathogenesis of NAFLD. Hepatology. 2021;74(4):2277\u20132286","journal-title":"Hepatology"},{"issue":"11","key":"10674_CR80","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1172\/JCI24798","volume":"115","author":"TI Novobrantseva","year":"2005","unstructured":"Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005;115(11):3072\u20133082","journal-title":"J Clin Invest"},{"key":"10674_CR81","doi-asserted-by":"publisher","first-page":"751802","DOI":"10.3389\/fendo.2021.751802","volume":"12","author":"S Hwang","year":"2021","unstructured":"Hwang S, Yun H, Moon S, Cho YE, Gao B. Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front Endocrinol (Lausanne). 2021;12:751802","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10674_CR82","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/hep.31680","volume":"74","author":"Y Cho","year":"2021","unstructured":"Cho Y, Szabo G. Two faces of neutrophils in liver disease development and progression. Hepatology. 2021;74(1):503\u2013512","journal-title":"Hepatology"},{"issue":"4","key":"10674_CR83","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165(4):1080\u20131088","journal-title":"Gastroenterology"},{"issue":"3","key":"10674_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members","year":"2021","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659\u2013689","journal-title":"J Hepatol"},{"issue":"5","key":"10674_CR85","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2023;77(5):1797\u20131835","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"10674_CR86","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cmet.2019.08.002","volume":"30","author":"R Loomba","year":"2019","unstructured":"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2019;30(3):607","journal-title":"Cell Metab"},{"issue":"6","key":"10674_CR87","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","volume":"78","author":"RM Carr","year":"2023","unstructured":"Carr RM, Li Y, Chau L, Friedman ES, Lee JJ, Adorini L, et al. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 2023;78(6):1843\u20131857","journal-title":"Hepatology"},{"issue":"5","key":"10674_CR88","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","volume":"159","author":"S Lang","year":"2020","unstructured":"Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020;159(5):1839\u20131852","journal-title":"Gastroenterology"},{"issue":"11","key":"10674_CR89","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.cgh.2022.11.030","volume":"21","author":"J Soppert","year":"2023","unstructured":"Soppert J, Brandt EF, Heussen NM, Barzakova E, Blank LM, Kuepfer L, et al. Blood endotoxin levels as biomarker of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(11):2746\u20132758","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10674_CR90","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","volume":"20","author":"H Tilg","year":"2020","unstructured":"Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40\u201354","journal-title":"Nat Rev Immunol"},{"key":"10674_CR91","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clnesp.2023.07.087","volume":"57","author":"A Mahapatro","year":"2023","unstructured":"Mahapatro A, Bawna F, Kumar V, Daryagasht AA, Gupta S, Raghuma N, et al. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses. Clin Nutr ESPEN. 2023;57:475\u2013486","journal-title":"Clin Nutr ESPEN"},{"key":"10674_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuad086","author":"E Amini-Salehi","year":"2023","unstructured":"Amini-Salehi E, Hassanipour S, Keivanlou MH, Shahdkar M, Orang Goorabzarmakhi M, Vakilpour A, et al. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. Nutr Rev. 2023. https:\/\/doi.org\/10.1093\/nutrit\/nuad086","journal-title":"Nutr Rev"},{"issue":"10","key":"10674_CR93","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","volume":"38","author":"L Rong","year":"2023","unstructured":"Rong L, Ch\u2019ng D, Jia P, Tsoi KKF, Wong SH, Sung JJY. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2023;38(10):1682\u20131694","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10674_CR94","first-page":"1488","volume":"13","author":"D Hu","year":"2023","unstructured":"Hu D, Zhao J, Zhang H, Wang G, Gu Z. Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment. Life (Basel). 2023;13(7):1488","journal-title":"Life (Basel)"},{"issue":"7","key":"10674_CR95","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","volume":"115","author":"L Craven","year":"2020","unstructured":"Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):1055\u20131065","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10674_CR96","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","volume":"4","author":"JJ Witjes","year":"2020","unstructured":"Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun. 2020;4(11):1578\u20131590","journal-title":"Hepatol Commun"},{"key":"10674_CR97","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","volume":"12","author":"L Xue","year":"2022","unstructured":"Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306","journal-title":"Front Cell Infect Microbiol"},{"key":"10674_CR98","doi-asserted-by":"publisher","first-page":"e072003","DOI":"10.1136\/bmj-2022-072003","volume":"380","author":"G Karam","year":"2023","unstructured":"Karam G, Agarwal A, Sadeghirad B, Jalink M, Hitchcock CL, Ge L, et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis. BMJ. 2023;380:e072003","journal-title":"BMJ"},{"issue":"1","key":"10674_CR99","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1210\/jc.2015-3351","volume":"101","author":"C Haro","year":"2016","unstructured":"Haro C, Montes-Borrego M, Rangel-Z\u00fa\u00f1iga OA, Alcal\u00e1-D\u00edaz JF, G\u00f3mez-Delgado F, P\u00e9rez-Mart\u00ednez P, et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab. 2016;101(1):233\u2013242","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10674_CR100","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.jhepr.2023.100909","volume":"5","author":"J Fujiki","year":"2023","unstructured":"Fujiki J, Schnabl B. Phage therapy: targeting intestinal bacterial microbiota for the treatment of liver diseases. JHEP Rep. 2023;5(12):100909","journal-title":"JHEP Rep"},{"issue":"1","key":"10674_CR101","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","volume":"14","author":"L Gan","year":"2023","unstructured":"Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14(1):3215","journal-title":"Nat Commun"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10674-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T23:59:01Z","timestamp":1732406341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10674-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":101,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10674"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10674-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Alisi declares she has no financial interests. Geoffrey McCaughan has no financial interests. Henning Gr\u00f8nb\u00e6k received research grants from Abbvie, Intercept, ARLA Food for Health, AIDS AIPHIA Development Services AG. Consultant and speaker\u2019s bureau at Ipsen, NOVO Nordisk, Pfizer, AstraZeneca. Data Monitoring Committee CARAMUS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}